AAV Vector NeuroD1 Delivery for Stroke Neuroregeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neuroinflammation following a stroke are inadequate in effectively reducing pro-inflammatory factors and promoting neuroregeneration in the central nervous system.
Innovation Solution
A recombinant adeno-associated virus (AAV) expression vector comprising a human GFAP promoter sequence operably linked to a nucleic acid encoding NeuroD1 is administered to the central nervous system to decrease neuroinflammation by downregulating pro-inflammatory factors and promoting the conversion of reactive astrocytes into functional neurons.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for neuroinflammation are used following a stroke, then the treatment protocol is simple and easy to administer, but the effectiveness in reducing pro-inflammatory factors and promoting neuroregeneration is inadequate
Solution Approach 1:
The patent uses AAV vectors as intermediary carriers to deliver NeuroD1 transcription factor to the central nervous system. The AAV vector acts as a mediator that transports the therapeutic gene across the blood-brain barrier and delivers it to target cells, thereby enhancing the effectiveness of neuroinflammation treatment without requiring complex surgical procedures or direct cellular manipulation
Solution Approach 2:
The patent employs the body's own reactive astrocytes as the target for NeuroD1 conversion, eliminating the need for external cell transplantation or complex tissue engineering. The endogenous glial cells serve themselves by being converted into functional neurons through the expressed NeuroD1 protein, simplifying the treatment protocol while enhancing regenerative effectiveness
2Productivity
If the AAV expression vector is administered to convert reactive astrocytes into functional neurons, then neuroregenerative efficiency is enhanced, but the complexity of the treatment increases
Solution Approach 1:
The patent changes the biological state of reactive astrocytes by introducing NeuroD1 expression, which alters their differentiation parameters and transforms them into functional neurons. This parameter change approach enhances neuroregenerative efficiency by converting existing damaged or dormant cells into active, functional neurons without requiring external cell sources or complex tissue construction
Solution Approach 2:
The AAV vector system serves multiple functions: it delivers the NeuroD1 gene, protects the genetic material during transport, enables expression in diverse cell types within the CNS, and provides sustained therapeutic effect. This multi-functionality enhances neuroregenerative efficiency while keeping the treatment protocol relatively simple compared to alternative approaches requiring multiple separate procedures
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 1E~1F
AI summary
Methods of treating the effects of disruption of normal blood flow in the CNS in an individual subject in need thereof are provided according to aspects of the present invention which include administering a therapeutically effective dose of exogenous NeuroDl to an area where normal blood flow has been disrupted. Compositions are provided including 1) a recombinant adeno-associ-ated adenovirus expression vector comprising a glial cell specific promoter operably linked to a nucleic acid encoding a site-specific recombinase and 2) a recombinant adeno-associated adenovirus expression vector comprising a ubiquitous promoter operably linked to a nucleic acid encoding NeuroDl, wherein the nucleic acid encoding NeuroDl is inverted and flanked by two sets of site-specific recombinase recognition sites such that action of the recombinase irreversibly inverts the nucleic acid encoding NeuroDl such that NeuroDl is expressed in a mammalian cell.